SAN DIEGO, Jan. 4, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that fidaxomicin, the Company's lead product candidate, has been granted orphan drug designation from the U.S.

SAN DIEGO, Nov. 30, 2010 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has completed the submission of its New Drug Application (NDA) to the U.S.

SAN DIEGO, Sept.